Zola Therapeutics
- Biotech or pharma, therapeutic R&D
Zola is a biotech company focused on modulating the innate immunity for oncology and autoimmune diseases. Our lead development candidate, Z-007, is a TLR7/8/9 RNA/DNA agonist in LNP that induces strong levels of IFNa (surrogate for CD8 T cell induction) without inflammatory cytokines. The program is ready to enter IND-enabling studies and is partially validated by the strong monotherapy efficacy of vidutolimod (a TLR9 agonist delivered in a VLP) in advanced melanoma, which was acquired by Regeneron for $250M in 2022.
Address
MassachusettsUnited States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}